CA2622745A1 - Systemes et methodes d'enrichissement d'analytes - Google Patents
Systemes et methodes d'enrichissement d'analytes Download PDFInfo
- Publication number
- CA2622745A1 CA2622745A1 CA002622745A CA2622745A CA2622745A1 CA 2622745 A1 CA2622745 A1 CA 2622745A1 CA 002622745 A CA002622745 A CA 002622745A CA 2622745 A CA2622745 A CA 2622745A CA 2622745 A1 CA2622745 A1 CA 2622745A1
- Authority
- CA
- Canada
- Prior art keywords
- analyte
- sample
- cells
- cell
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 152
- 239000012491 analyte Substances 0.000 claims abstract description 212
- 238000000926 separation method Methods 0.000 claims abstract description 158
- 230000001605 fetal effect Effects 0.000 claims abstract description 120
- 230000005856 abnormality Effects 0.000 claims abstract description 14
- 239000000523 sample Substances 0.000 claims description 357
- 210000004027 cell Anatomy 0.000 claims description 340
- 210000004369 blood Anatomy 0.000 claims description 148
- 239000008280 blood Substances 0.000 claims description 148
- 239000012530 fluid Substances 0.000 claims description 95
- 239000003153 chemical reaction reagent Substances 0.000 claims description 73
- 206010028980 Neoplasm Diseases 0.000 claims description 68
- 210000003743 erythrocyte Anatomy 0.000 claims description 62
- 230000005291 magnetic effect Effects 0.000 claims description 54
- 201000011510 cancer Diseases 0.000 claims description 52
- 210000000349 chromosome Anatomy 0.000 claims description 46
- 238000004458 analytical method Methods 0.000 claims description 43
- 239000006249 magnetic particle Substances 0.000 claims description 40
- 238000003491 array Methods 0.000 claims description 39
- 210000002919 epithelial cell Anatomy 0.000 claims description 34
- 210000003754 fetus Anatomy 0.000 claims description 33
- 230000008774 maternal effect Effects 0.000 claims description 29
- 210000000265 leukocyte Anatomy 0.000 claims description 28
- 210000001772 blood platelet Anatomy 0.000 claims description 18
- 210000000601 blood cell Anatomy 0.000 claims description 17
- 210000000130 stem cell Anatomy 0.000 claims description 17
- 201000010374 Down Syndrome Diseases 0.000 claims description 15
- 238000003745 diagnosis Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 14
- 210000001766 X chromosome Anatomy 0.000 claims description 13
- 239000012502 diagnostic product Substances 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 244000052769 pathogen Species 0.000 claims description 13
- 238000003793 prenatal diagnosis Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 206010044688 Trisomy 21 Diseases 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 12
- 210000002889 endothelial cell Anatomy 0.000 claims description 12
- 108060003196 globin Proteins 0.000 claims description 12
- 102000018146 globin Human genes 0.000 claims description 12
- 239000011324 bead Substances 0.000 claims description 11
- 238000002372 labelling Methods 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 10
- 230000036541 health Effects 0.000 claims description 10
- 230000001717 pathogenic effect Effects 0.000 claims description 10
- 230000035935 pregnancy Effects 0.000 claims description 10
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims description 9
- 201000000582 Retinoblastoma Diseases 0.000 claims description 9
- 210000002593 Y chromosome Anatomy 0.000 claims description 9
- 230000002068 genetic effect Effects 0.000 claims description 9
- 238000002493 microarray Methods 0.000 claims description 9
- 230000035945 sensitivity Effects 0.000 claims description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 8
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 8
- 201000009928 Patau syndrome Diseases 0.000 claims description 8
- 206010044686 Trisomy 13 Diseases 0.000 claims description 8
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 claims description 8
- 238000004590 computer program Methods 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 8
- 239000002853 nucleic acid probe Substances 0.000 claims description 8
- 208000000398 DiGeorge Syndrome Diseases 0.000 claims description 7
- 201000006360 Edwards syndrome Diseases 0.000 claims description 7
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 7
- 201000001388 Smith-Magenis syndrome Diseases 0.000 claims description 7
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 claims description 7
- 208000026928 Turner syndrome Diseases 0.000 claims description 7
- 206010049644 Williams syndrome Diseases 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 210000004700 fetal blood Anatomy 0.000 claims description 7
- 230000014759 maintenance of location Effects 0.000 claims description 7
- 206010053884 trisomy 18 Diseases 0.000 claims description 7
- 201000000866 velocardiofacial syndrome Diseases 0.000 claims description 7
- 208000009575 Angelman syndrome Diseases 0.000 claims description 6
- 208000003449 Classical Lissencephalies and Subcortical Band Heterotopias Diseases 0.000 claims description 6
- 208000017924 Klinefelter Syndrome Diseases 0.000 claims description 6
- 201000004246 Miller-Dieker lissencephaly syndrome Diseases 0.000 claims description 6
- 208000035022 Miller-Dieker syndrome Diseases 0.000 claims description 6
- 208000001001 X-linked ichthyosis Diseases 0.000 claims description 6
- 208000026079 recessive X-linked ichthyosis Diseases 0.000 claims description 6
- 239000002689 soil Substances 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 201000007493 Kallmann syndrome Diseases 0.000 claims description 5
- 206010053142 Olfacto genital dysplasia Diseases 0.000 claims description 5
- 230000001788 irregular Effects 0.000 claims description 5
- 239000012807 PCR reagent Substances 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 4
- 239000007850 fluorescent dye Substances 0.000 claims description 4
- 210000000497 foam cell Anatomy 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 241000710929 Alphavirus Species 0.000 claims description 3
- 241000589562 Brucella Species 0.000 claims description 3
- 241000722910 Burkholderia mallei Species 0.000 claims description 3
- 241001136175 Burkholderia pseudomallei Species 0.000 claims description 3
- 241001647378 Chlamydia psittaci Species 0.000 claims description 3
- 208000031404 Chromosome Aberrations Diseases 0.000 claims description 3
- 241000193155 Clostridium botulinum Species 0.000 claims description 3
- 241000606678 Coxiella burnetii Species 0.000 claims description 3
- 241000223936 Cryptosporidium parvum Species 0.000 claims description 3
- 241001115402 Ebolavirus Species 0.000 claims description 3
- 241001646719 Escherichia coli O157:H7 Species 0.000 claims description 3
- 108010044495 Fetal Hemoglobin Proteins 0.000 claims description 3
- 241000589602 Francisella tularensis Species 0.000 claims description 3
- 241000526636 Nipah henipavirus Species 0.000 claims description 3
- 241000150452 Orthohantavirus Species 0.000 claims description 3
- 108010026552 Proteome Proteins 0.000 claims description 3
- 241000606697 Rickettsia prowazekii Species 0.000 claims description 3
- 241000607142 Salmonella Species 0.000 claims description 3
- 208000001203 Smallpox Diseases 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 3
- 208000037280 Trisomy Diseases 0.000 claims description 3
- 241000607626 Vibrio cholerae Species 0.000 claims description 3
- 241000607479 Yersinia pestis Species 0.000 claims description 3
- 229940074375 burkholderia mallei Drugs 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 238000004891 communication Methods 0.000 claims description 3
- 230000009089 cytolysis Effects 0.000 claims description 3
- 230000009977 dual effect Effects 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 229940118764 francisella tularensis Drugs 0.000 claims description 3
- 230000014509 gene expression Effects 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 239000002861 polymer material Substances 0.000 claims description 3
- 238000009598 prenatal testing Methods 0.000 claims description 3
- 229940046939 rickettsia prowazekii Drugs 0.000 claims description 3
- 210000002993 trophoblast Anatomy 0.000 claims description 3
- 201000006266 variola major Diseases 0.000 claims description 3
- 229940118696 vibrio cholerae Drugs 0.000 claims description 3
- 241000193738 Bacillus anthracis Species 0.000 claims description 2
- 206010008805 Chromosomal abnormalities Diseases 0.000 claims description 2
- 241000712902 Lassa mammarenavirus Species 0.000 claims description 2
- 102000003800 Selectins Human genes 0.000 claims description 2
- 108090000184 Selectins Proteins 0.000 claims description 2
- 208000006254 Wolf-Hirschhorn Syndrome Diseases 0.000 claims description 2
- 229940065181 bacillus anthracis Drugs 0.000 claims description 2
- 230000009395 genetic defect Effects 0.000 claims description 2
- 238000010191 image analysis Methods 0.000 claims description 2
- 230000036266 weeks of gestation Effects 0.000 claims description 2
- 102000049320 CD36 Human genes 0.000 claims 1
- 108010045374 CD36 Antigens Proteins 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 41
- 239000000306 component Substances 0.000 description 37
- 230000027455 binding Effects 0.000 description 25
- 239000002245 particle Substances 0.000 description 22
- 238000001514 detection method Methods 0.000 description 19
- 239000000758 substrate Substances 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 238000013461 design Methods 0.000 description 15
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 14
- 229910052710 silicon Inorganic materials 0.000 description 14
- 239000010703 silicon Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 12
- 230000000717 retained effect Effects 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 239000010410 layer Substances 0.000 description 10
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 9
- 102100035716 Glycophorin-A Human genes 0.000 description 9
- 108091005250 Glycophorins Proteins 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000004626 scanning electron microscopy Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 238000005530 etching Methods 0.000 description 8
- -1 gaseous Substances 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 230000002934 lysing effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 239000002699 waste material Substances 0.000 description 8
- 239000000696 magnetic material Substances 0.000 description 7
- 229920002120 photoresistant polymer Polymers 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000004907 flux Effects 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 235000012431 wafers Nutrition 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- 238000000206 photolithography Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 208000032170 Congenital Abnormalities Diseases 0.000 description 3
- 239000004593 Epoxy Substances 0.000 description 3
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002102 nanobead Substances 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000002096 quantum dot Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229910052712 strontium Inorganic materials 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000001039 wet etching Methods 0.000 description 3
- 229910000859 α-Fe Inorganic materials 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 206010008263 Cervical dysplasia Diseases 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
- 208000007569 Giant Cell Tumors Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000037147 Hypercalcaemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000007054 Medullary Carcinoma Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000005890 Neuroma Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 201000010208 Seminoma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 201000005188 adrenal gland cancer Diseases 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000002669 amniocentesis Methods 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 210000005168 endometrial cell Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000005294 ferromagnetic effect Effects 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 201000008361 ganglioneuroma Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 230000000148 hypercalcaemia Effects 0.000 description 2
- 208000030915 hypercalcemia disease Diseases 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 201000004933 in situ carcinoma Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 201000002529 islet cell tumor Diseases 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 201000004962 larynx cancer Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 239000012762 magnetic filler Substances 0.000 description 2
- 230000005389 magnetism Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 208000026037 malignant tumor of neck Diseases 0.000 description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 208000028591 pheochromocytoma Diseases 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 208000037244 polycythemia vera Diseases 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 208000030266 primary brain neoplasm Diseases 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 208000026485 trisomy X Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- KFEUJDWYNGMDBV-UHFFFAOYSA-N (N-Acetyl)-glucosamin-4-beta-galaktosid Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 KFEUJDWYNGMDBV-UHFFFAOYSA-N 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102100030886 Complement receptor type 1 Human genes 0.000 description 1
- 206010011385 Cri-du-chat syndrome Diseases 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100039373 Membrane cofactor protein Human genes 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000001804 Monosomy 5p Diseases 0.000 description 1
- 208000016679 Monosomy X Diseases 0.000 description 1
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 description 1
- HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 208000037492 Sex Chromosome Aberrations Diseases 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 208000026487 Triploidy Diseases 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- QJVKUMXDEUEQLH-UHFFFAOYSA-N [B].[Fe].[Nd] Chemical compound [B].[Fe].[Nd] QJVKUMXDEUEQLH-UHFFFAOYSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 244000000022 airborne pathogen Species 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 244000078885 bloodborne pathogen Species 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 210000002358 circulating endothelial cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- AVMBSRQXOWNFTR-UHFFFAOYSA-N cobalt platinum Chemical compound [Pt][Co][Pt] AVMBSRQXOWNFTR-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000000708 deep reactive-ion etching Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000005347 demagnetization Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000009429 electrical wiring Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 108010045676 holotransferrin Proteins 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010849 ion bombardment Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 239000006247 magnetic powder Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000005459 micromachining Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000013206 minimal dilution Methods 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- PHQOGHDTIVQXHL-UHFFFAOYSA-N n'-(3-trimethoxysilylpropyl)ethane-1,2-diamine Chemical compound CO[Si](OC)(OC)CCCNCCN PHQOGHDTIVQXHL-UHFFFAOYSA-N 0.000 description 1
- 229910001172 neodymium magnet Inorganic materials 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
- 210000000948 non-nucleated cell Anatomy 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000009609 prenatal screening Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013545 self-assembled monolayer Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 238000002174 soft lithography Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005845 steroid sulfates Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000035581 susceptibility to neural tube defects Diseases 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
- B01L2200/0668—Trapping microscopic beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0864—Configuration of multiple channels and/or chambers in a single devices comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/043—Moving fluids with specific forces or mechanical means specific forces magnetic forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/08—Regulating or influencing the flow resistance
- B01L2400/084—Passive control of flow resistance
- B01L2400/086—Passive control of flow resistance using baffles or other fixed flow obstructions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C2201/00—Details of magnetic or electrostatic separation
- B03C2201/18—Magnetic separation whereby the particles are suspended in a liquid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C2201/00—Details of magnetic or electrostatic separation
- B03C2201/26—Details of magnetic or electrostatic separation for use in medical or biological applications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
- G01N2001/4088—Concentrating samples by other techniques involving separation of suspended solids filtration
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
- G01N2333/805—Haemoglobins; Myoglobins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Fluid Mechanics (AREA)
- Oncology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/229,037 US20070059774A1 (en) | 2005-09-15 | 2005-09-15 | Kits for Prenatal Testing |
US11/229,328 | 2005-09-15 | ||
US11/229,336 US20070059781A1 (en) | 2005-09-15 | 2005-09-15 | System for size based separation and analysis |
US11/228,454 US20070059716A1 (en) | 2005-09-15 | 2005-09-15 | Methods for detecting fetal abnormality |
US11/228,454 | 2005-09-15 | ||
US11/229,332 US20070059719A1 (en) | 2005-09-15 | 2005-09-15 | Business methods for prenatal Diagnosis |
US11/229,332 | 2005-09-15 | ||
US11/229,037 | 2005-09-15 | ||
US11/228,462 US20070059680A1 (en) | 2005-09-15 | 2005-09-15 | System for cell enrichment |
US11/229,336 | 2005-09-15 | ||
US11/228,462 | 2005-09-15 | ||
US11/229,328 US20070059718A1 (en) | 2005-09-15 | 2005-09-15 | Systems and methods for enrichment of analytes |
PCT/US2006/036202 WO2007035585A2 (fr) | 2005-09-15 | 2006-09-15 | Systemes et methodes d'enrichissement d'analytes |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2622745A1 true CA2622745A1 (fr) | 2007-03-29 |
Family
ID=37889398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002622745A Abandoned CA2622745A1 (fr) | 2005-09-15 | 2006-09-15 | Systemes et methodes d'enrichissement d'analytes |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1931800A4 (fr) |
JP (1) | JP2009509143A (fr) |
AU (1) | AU2006292394A1 (fr) |
CA (1) | CA2622745A1 (fr) |
IL (1) | IL190090A0 (fr) |
WO (1) | WO2007035585A2 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090136982A1 (en) | 2005-01-18 | 2009-05-28 | Biocept, Inc. | Cell separation using microchannel having patterned posts |
US8158410B2 (en) | 2005-01-18 | 2012-04-17 | Biocept, Inc. | Recovery of rare cells using a microchannel apparatus with patterned posts |
WO2006078470A2 (fr) | 2005-01-18 | 2006-07-27 | Biocept, Inc. | Separation de cellules utilisant un microcanal comportant des tiges disposees selon un motif particulier |
EP1874920A4 (fr) * | 2005-04-05 | 2009-11-04 | Cellpoint Diagnostics | Dispositifs et procédés permettant d'enrichir et de modifier des cellules tumorales circulantes et d'autres particules |
US20070196820A1 (en) | 2005-04-05 | 2007-08-23 | Ravi Kapur | Devices and methods for enrichment and alteration of cells and other particles |
US7695956B2 (en) | 2006-01-12 | 2010-04-13 | Biocept, Inc. | Device for cell separation and analysis and method of using |
US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
EP2061801A4 (fr) * | 2006-06-14 | 2009-11-11 | Living Microsystems Inc | Diagnostic d'anomalies fetales par une analyse par hybridation genomique comparative |
FR2931141B1 (fr) * | 2008-05-13 | 2011-07-01 | Commissariat Energie Atomique | Systeme microfluidique et procede pour le tri d'amas de cellules et de preference pour leur encapsulation en continu suite a leur tri |
WO2010041231A2 (fr) * | 2008-10-10 | 2010-04-15 | Cnrs-Dae | Dispositif de tri de cellules |
US9347931B2 (en) * | 2009-04-23 | 2016-05-24 | Dublin City University | Lateral flow assay device for coagulation monitoring and method thereof |
SG184592A1 (en) * | 2011-03-18 | 2012-10-30 | Univ Singapore | Isolating target cells from a biological fluid |
EP2593787B1 (fr) | 2010-07-16 | 2018-07-04 | Stichting VUmc | Méthode d'analyser une prise de sang d'un sujet pour la présence d'un marqueur de la maladie |
JP5626727B2 (ja) * | 2010-09-21 | 2014-11-19 | 国立大学法人東京農工大学 | 微量血液からの白血球ポピュレーション解析法 |
JP5934726B2 (ja) | 2011-03-18 | 2016-06-15 | フェレニヒング フォール クリステリック ホーヘル オンデルウィス,ウェテンシャペリク オンデルツォーケン パティエンテンツォルフ | 疾患マーカーの存在を被験者の血液サンプルで分析する方法 |
WO2014145152A2 (fr) | 2013-03-15 | 2014-09-18 | Gpb Scientific, Llc | Traitement microfluidique intégré de particules |
WO2014145075A2 (fr) | 2013-03-15 | 2014-09-18 | The Trustees Of Princeton University | Méthodes et dispositifs de purification à rendement élevé |
US20150064153A1 (en) | 2013-03-15 | 2015-03-05 | The Trustees Of Princeton University | High efficiency microfluidic purification of stem cells to improve transplants |
JP6403190B2 (ja) * | 2013-08-06 | 2018-10-10 | 旭化成株式会社 | マイクロ流路構造体及び粒子の分離方法 |
ES1111981Y (es) | 2014-05-22 | 2014-09-03 | Ayet Félix Checa | Protesis quirurgica para el tratamiento de hernias inguinales |
US10976232B2 (en) | 2015-08-24 | 2021-04-13 | Gpb Scientific, Inc. | Methods and devices for multi-step cell purification and concentration |
EP4035762B1 (fr) | 2015-09-09 | 2023-11-01 | Drawbridge Health, Inc. | Dispositifs pour la collecte, la stabilisation et la conservation d'échantillons |
SG10201911879UA (en) | 2017-01-10 | 2020-01-30 | Drawbridge Health Inc | Devices, systems, and methods for sample collection |
AU2018323875A1 (en) | 2017-09-01 | 2020-04-23 | Gpb Scientific, Inc. | Methods for preparing therapeutically active cells using microfluidics |
JPWO2020184500A1 (fr) * | 2019-03-14 | 2020-09-17 | ||
JP7455339B2 (ja) | 2020-09-29 | 2024-03-26 | Nok株式会社 | 白血球捕捉デバイス |
CN116312809B (zh) * | 2023-04-10 | 2023-08-29 | 杭州美赛生物医药科技有限公司 | 一种基于抗体偶联磁珠的细胞筛选方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4508625A (en) * | 1982-10-18 | 1985-04-02 | Graham Marshall D | Magnetic separation using chelated magnetic ions |
US5715946A (en) * | 1995-06-07 | 1998-02-10 | Reichenbach; Steven H. | Method and apparatus for sorting particles suspended in a fluid |
US6074827A (en) * | 1996-07-30 | 2000-06-13 | Aclara Biosciences, Inc. | Microfluidic method for nucleic acid purification and processing |
CA2264389A1 (fr) * | 1996-09-04 | 1998-03-12 | Technical University Of Denmark | Systeme a microdebit pour separation et analyse de particules |
US6613581B1 (en) * | 1999-08-26 | 2003-09-02 | Caliper Technologies Corp. | Microfluidic analytic detection assays, devices, and integrated systems |
CA2424941A1 (fr) * | 2000-10-10 | 2002-04-18 | Aviva Biosciences Corporation | Systeme a biopuce integree pour la preparation et l'analyse d'echantillons |
ATE479490T1 (de) * | 2001-10-11 | 2010-09-15 | Aviva Biosciences Corp | Verfahren zum trennen von seltenen zellen von fluidproben |
AU2003277153A1 (en) * | 2002-09-27 | 2004-04-19 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
ES2341103T3 (es) * | 2002-10-23 | 2010-06-15 | The Trustees Of Princeton University | Procedimiento de separacion continua de particulas usando reticulados de obstaculos alineados asimetricamente respecto a campos. |
-
2006
- 2006-09-15 WO PCT/US2006/036202 patent/WO2007035585A2/fr active Application Filing
- 2006-09-15 AU AU2006292394A patent/AU2006292394A1/en not_active Abandoned
- 2006-09-15 EP EP06803736A patent/EP1931800A4/fr not_active Withdrawn
- 2006-09-15 CA CA002622745A patent/CA2622745A1/fr not_active Abandoned
- 2006-09-15 JP JP2008531396A patent/JP2009509143A/ja not_active Withdrawn
-
2008
- 2008-03-11 IL IL190090A patent/IL190090A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2009509143A (ja) | 2009-03-05 |
IL190090A0 (en) | 2008-08-07 |
WO2007035585A3 (fr) | 2007-11-29 |
EP1931800A2 (fr) | 2008-06-18 |
AU2006292394A1 (en) | 2007-03-29 |
WO2007035585A2 (fr) | 2007-03-29 |
EP1931800A4 (fr) | 2011-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070059683A1 (en) | Veterinary diagnostic system | |
US20070059718A1 (en) | Systems and methods for enrichment of analytes | |
US20100273675A1 (en) | Methods for detecting fetal abnormality | |
US20070059680A1 (en) | System for cell enrichment | |
US20070059774A1 (en) | Kits for Prenatal Testing | |
US20070059719A1 (en) | Business methods for prenatal Diagnosis | |
US20070059781A1 (en) | System for size based separation and analysis | |
CA2622745A1 (fr) | Systemes et methodes d'enrichissement d'analytes | |
US11725180B2 (en) | Microfluidic sorting using high gradient magnetic fields | |
US20060223178A1 (en) | Devices and methods for magnetic enrichment of cells and other particles | |
US20070196820A1 (en) | Devices and methods for enrichment and alteration of cells and other particles | |
Serra et al. | The power of solid supports in multiphase and droplet-based microfluidics: towards clinical applications | |
US9140697B2 (en) | Device for capturing circulating cells | |
US20190137494A1 (en) | Microfluidic devices for isolating particles | |
US8124015B2 (en) | Multiplexed, microfluidic molecular assay device and assay method | |
US20110212440A1 (en) | Cell sorting device | |
JP2009511001A (ja) | 細胞及びその他の粒子を磁気濃縮するためのデバイス並びに方法 | |
WO2010140706A1 (fr) | Systèmes d'opérations biologiques et industrielles | |
JP2002503334A (ja) | 粒子の分離と分析用のマイクロフローシステム | |
WO2011063416A2 (fr) | Dispositifs microfluidiques destinés à capturer des composants d'un échantillon biologique | |
JP7486823B2 (ja) | 粒子捕捉システムおよび方法 | |
DESCROIX | An innovative approach for magnetic solid supports handling in droplet microfluidics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20120917 |